AstraZeneca, Lilly, J&J dinged by FDA SGLT2 alert
This article was originally published in Scrip
Executive Summary
Shares of AstraZeneca, Johnson and Johnson and Lilly took slight hits on 15 May after the FDA warned the firms' sodium-glucose cotransporter-2 (SGLT2) inhibitors – a fairly new class of drugs used to treat type 2 diabetes – may cause ketoacidosis, a serious condition in which the body produces ketones, or high levels of blood acids, which may lead to hospitalization.